$ 4,000,000,000! AstraZeneca announced the acquisition of Acerta 55% stake in the pharmaceutical

AstraZeneca will spread industry had $ 5 billion takeover rumors finally sit Acerta real difference is that the actual offer AstraZeneca is $ 4 billion, the acquisition of 55% stake Acerta. Acerta is a little-known biotechnology company, there were no drugs to the market, the main development of cancer and autoimmune related drugs. Acerta Currently in development of BTK inhibitors acalabrutinib has been granted FDA Orphan Drug treatment of mantle cell lymphoma qualify for a public analysts are optimistic.

Under the agreement, AstraZeneca will pay Acerta 25 亿 美元 advances, then approved by the FDA on or before the end of 2018, and then unconditionally pay $ 1.5 billion in acalabrutinib.

Under the agreement, AstraZeneca received only 55% of the shares Acerta, but AstraZeneca can still purchase the remaining 45% stake in the company by Acerta shareholders. AstraZeneca full acquisition Acerta specific time can not be determined, depending on acalabrutinib simultaneously approved in the US and Europe time. Once ripe, AstraZeneca intends to pay $ 3 billion net to acquire the remaining 45% stake.

Observe the agreement, not difficult to find acalabrutinib completely awful merger achievement core drugs. Currently acalabrutinib are all kinds of leukemia, lymphoma clinical trials, but also with Merck's tumor immune drugs Keytruda (pembrolizumab) carried out a joint drug test. Acalabrutinib BTK inhibitors are a class with Abbvie / Johnson leukemia drugs Imbruvica (ibrutinib) mechanism of action is similar, is generally considered peak sales will be more than 5 billion US dollars.

Early clinical data results Acalabrutinib also gratifying. Recently published in the New England Journal of Medicine Phase I / II clinical trial results showed that the response rate in patients with chronic lymphocytic leukemia drug has reached 95%, while adult leukemia, chronic lymphocytic leukemia is the most common one.